Epigenomics AG / Key word(s): Restructure of Company/Financing
15-Feb-2023 / 11:13 CET/CEST
Epigenomics resolves on restructuring to minimize costs
Berlin, Germany, February 15, 2023 – Today Epigenomics AG (Frankfurt Prime Standard: ECX1, OTCQX: EPGNY; the “Company”) has decided to restructure the Company and to significantly reduce the Company’s operations (the “Restructuring”). The Restructuring is carried out to minimize the Company’s costs. In addition, this is intended to extend the time period available to the Company to secure financing for the further development of the “Next-Gen”-test for detecting colorectal cancer (CRC).
As part of the restructuring, it is planned that the Company will undertake the following measures in particular:
On this basis, the executive board expects revenues for 2023 to be in the range of EUR 60,000 to 200,000. Otherwise, the financial outlook will be announced as part of the Annual Report.
Note on forward-looking statements
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
15-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 30 24345-0|
|Fax:||+49 30 24345-555|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1560333|
|End of Announcement||EQS News Service|